TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company